DALLAS--(BUSINESS WIRE)--Peloton Therapeutics, Inc., today announced the appointment of Alan A. Musso as Chief Financial Officer (CFO), effective September 4, 2018. Mr. Musso brings significant financial expertise and operational leadership to Peloton. As Peloton’s first CFO, Mr. Musso will be responsible for corporate financing activities, investor relations, accounting, human resources, information systems, and operations. He will report to John A. Josey, Ph.D., Peloton’s Chief Executive Officer (CEO).
“We are delighted to welcome Alan to Peloton in this strategic leadership role as we continue to advance our pipeline of novel oral HIF-2α inhibitors,” said John Josey. “He is an accomplished biotechnology CFO with an impressive track record of successful public and private financings, business development and effective team building at development-stage companies. The Board of Directors and I are confident he will be an excellent addition to our senior management team.”
Mr. Musso has 30 years of biotechnology and pharmaceutical industry experience, including capital raising, corporate partnering, finance, strategy, and the financial stewardship of publicly-traded companies. He joins Peloton from Bellicum Pharmaceuticals, Inc., a biopharmaceutical company focused on cellular cancer immunotherapies, where he served as CFO and Treasurer since November 2014 and successfully raised $300 million via an IPO and follow-on financings. Prior to Bellicum, he was CFO at Targacept where he led its 2006 IPO and multiple public and private financings. Earlier in his career, he held a variety of key managerial positions in finance and accounting at Osiris Therapeutics, Cato Research, Duramed Pharmaceuticals and Pfizer. Mr. Musso is a Certified Public Accountant (CPA) and began his career with KPMG. Mr. Musso received a B.S. in Accounting from Saint Mary's College of California, and a master's degree from the American Graduate School of International Management.
Peloton’s drug discovery and development efforts focus on identifying novel compounds capable of modulating complex protein-protein interactions that drive disease which have eluded conventional small molecule approaches. The company is currently evaluating PT2977, a once-daily oral inhibitor of HIF-2α, in an international Phase 2 trial in VHL-associated renal cell carcinoma (RCC) and a Phase 1 trial for the treatment of RCC.
About Peloton Therapeutics
Peloton Therapeutics, Inc. is a clinical-stage pharmaceutical company that is translating groundbreaking scientific insights into first-in-class oral medicines for patients with cancer and other serious or life-threatening conditions. The company’s lead development program is evaluating the only clinical-stage small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney cancer and a wide variety of other disorders. Peloton is also progressing several research programs by building upon its success in inhibiting HIF-2α, which was previously thought to be intractable using small molecules.
To learn more about Peloton Therapeutics, visit www.pelotontherapeutics.com.
© 2018 Peloton Therapeutics, Inc.
All Rights Reserved